[go: up one dir, main page]

MX2022012021A - Peptidos de dominios knob autonomos. - Google Patents

Peptidos de dominios knob autonomos.

Info

Publication number
MX2022012021A
MX2022012021A MX2022012021A MX2022012021A MX2022012021A MX 2022012021 A MX2022012021 A MX 2022012021A MX 2022012021 A MX2022012021 A MX 2022012021A MX 2022012021 A MX2022012021 A MX 2022012021A MX 2022012021 A MX2022012021 A MX 2022012021A
Authority
MX
Mexico
Prior art keywords
autonomous
isolated
domain peptides
knob domain
formulations
Prior art date
Application number
MX2022012021A
Other languages
English (en)
Inventor
Alastair David Griffiths Lawson
Alexander Macpherson
Anthony Scott-Tucker
Anastasios Spiliotopoulos
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004462.4A external-priority patent/GB202004462D0/en
Priority claimed from GBGB2008095.8A external-priority patent/GB202008095D0/en
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MX2022012021A publication Critical patent/MX2022012021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a fragmentos aislados de anticuerpos, en particular a dominios knob aislados de CDR-H3 bovina ultralarga o porciones de la misma que se unen a un antígeno de interés, y formulaciones que comprenden los mismos. La descripción se refiere, además, al uso de formulaciones y fragmentos de anticuerpos aislados en tratamientos. La presente descripción también se extiende a métodos para preparar dichos fragmentos de anticuerpos aislados.
MX2022012021A 2020-03-27 2021-03-26 Peptidos de dominios knob autonomos. MX2022012021A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2004462.4A GB202004462D0 (en) 2020-03-27 2020-03-27 Antibody fragments
GBGB2008095.8A GB202008095D0 (en) 2020-05-29 2020-05-29 Antibody fragments
PCT/EP2021/057946 WO2021191424A1 (en) 2020-03-27 2021-03-26 Autonomous knob domain peptides

Publications (1)

Publication Number Publication Date
MX2022012021A true MX2022012021A (es) 2022-10-27

Family

ID=75339748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012021A MX2022012021A (es) 2020-03-27 2021-03-26 Peptidos de dominios knob autonomos.

Country Status (14)

Country Link
US (1) US20240024520A1 (es)
EP (1) EP4126936A1 (es)
JP (1) JP2023519576A (es)
KR (1) KR20220160069A (es)
CN (1) CN115667298A (es)
AU (1) AU2021245031A1 (es)
BR (1) BR112022019047A2 (es)
CA (1) CA3175034A1 (es)
CL (1) CL2022002635A1 (es)
CO (1) CO2022015049A2 (es)
IL (1) IL296732A (es)
MX (1) MX2022012021A (es)
TW (1) TW202202520A (es)
WO (1) WO2021191424A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4630436A1 (en) * 2022-12-05 2025-10-15 Pelican Technology Holdings, Inc. Methods for expression of fusion-free bovine ultralong cdr3 scaffold
AU2024290842A1 (en) 2023-07-03 2026-01-15 UCB Biopharma SRL Engineered aav capsid proteins
GB202314896D0 (en) 2023-09-28 2023-11-15 UCB Biopharma SRL Knob domain proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP4677187B2 (ja) 2001-11-13 2011-04-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規なアデノ随伴ウイルス（ａａｖ）７配列、それを含むベクターおよびそれらの使用
WO2003052051A2 (en) 2001-12-17 2003-06-26 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP2007536898A (ja) 2003-07-01 2007-12-20 セルテック アール アンド ディ リミテッド 修飾抗体Ｆａｂフラグメント
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
NZ545628A (en) 2003-09-30 2009-04-30 Univ Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
EP2359866B1 (en) 2005-04-07 2013-07-17 The Trustees of The University of Pennsylvania Modified AAV rh48 capsids, compositions containing same and uses thereof
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
HUE033438T2 (en) 2008-09-26 2017-11-28 Ucb Biopharma Sprl Biological products
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CN103946237B (zh) 2011-11-11 2017-04-12 Ucb医药有限公司 白蛋白结合抗体及其结合片段
CA2862979A1 (en) * 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US20140050720A1 (en) * 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US10048253B2 (en) 2012-06-28 2018-08-14 Ucb Biopharma Sprl Method for identifying compounds of therapeutic interest
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US10259863B2 (en) * 2013-01-11 2019-04-16 The California Institute For Biomedical Research Bovine fusion antibodies
GB201310544D0 (en) 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
CN111518199A (zh) * 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
DK3476942T3 (da) * 2017-10-27 2022-04-19 Trianni Inc Lange kimlinje-dh-gener og antistoffer med lang hcdr3
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody

Also Published As

Publication number Publication date
AU2021245031A1 (en) 2022-11-03
CN115667298A (zh) 2023-01-31
IL296732A (en) 2022-11-01
US20240024520A1 (en) 2024-01-25
WO2021191424A1 (en) 2021-09-30
EP4126936A1 (en) 2023-02-08
KR20220160069A (ko) 2022-12-05
CO2022015049A2 (es) 2022-11-08
BR112022019047A2 (pt) 2022-11-01
TW202202520A (zh) 2022-01-16
JP2023519576A (ja) 2023-05-11
CL2022002635A1 (es) 2023-03-31
CA3175034A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
MY201526A (en) Anti-trem2 antibodies and methods of use thereof
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
MX2020009121A (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de produccion de anticuerpos anti-sirpa v1.
NO994983L (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
MX2022012021A (es) Peptidos de dominios knob autonomos.
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
SG196697A1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
JO3351B1 (ar) بروتينات رابطة مستضِدة قادرة على ربط مكونات ليمفاوية سدوية سُعترية الشكل
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
WO2020172621A8 (en) Cd33 antibodies and methods of using the same to treat cancer
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2021022083A3 (en) Anti-ms4a4a antibodies and methods of use thereof
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
MX2022014243A (es) Proteina de union al antigeno st2.
MX2023005386A (es) Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina.
MX2022007156A (es) Metodos de uso de anticuerpos anti-cd33.
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
MX2025008002A (es) Construcciones de anticuerpos específicos para el cúmulo de diferenciación 19 (cd19) y composiciones de estos
WO2021067633A3 (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
WO2024148232A3 (en) Anti-il18 binding protein antibodies and methods of use thereof